Robotic Partial Cystectomy Safe After Neoadjuvant Chemotherapy for MIBC – Oncology Nurse Advisor
Small retrospective study showed that the procedure achieved negative surgical margins in all cases, with no patients requiring salvage cystectomy.
Related Articles
Blood Global Hematology | American Society of Hematology
Jorge Cortes, MD director of the Georgia Cancer Center at Augusta University and inaugural Editor-in-Chief of Blood Global Hematology, shares his vision for the journal…
Flonoltinib Maleate Provides Durable Spleen Reduction and Symptom Improvement in Myelofibrosis
Flonoltinib maleate generated rapid clinical benefits, including spleen volume reduction and symptom improvement, for patients with myelofibrosis.
Intraoperative Fluid Balance and Perioperative Complications in Ovarian Cancer Surgery
Annals of Surgical Oncology – Fluid overload and hypovolemia promote postoperative complications in patients undergoing cytoreductive surgery for ovarian cancer. In the present study, postoperative…
Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q) MDS
Lenalidomide plus luspatercept demonstrated safety, tolerability, and efficacy in patients with non-del(5q) myelodysplastic syndrome.
FcRn and Myasthenia Gravis
The role of neonatal fragment crystallizable receptor (FcRn) in myasthenia gravis (MG) and treatment options
American Society of Hematology: building a comprehensive minority recruitment and retention professional program
Abstract. In 2003, the Institute of Medicine noted the need to improve workforce diversity. The American Society of Hematology (ASH) responded by developin
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Key PointsIptacopan monotherapy is cost saving for anti-C5–treated patients with suboptimal response vs continuation of C5 inhibitors.Improved quality of l
Novel Therapies and Combinations Lead the Way in Women’s Cancers in 2024
Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 blockade, or the use of fam-trastuzumab deruxtecan-nxki in endometrial cancer.
Precision Medicine in AML: An Abundance of Options | Blood Cancers Today
Experts delve deeper into the evolving treatment landscape, focusing on the transformative role of targeted therapies.
Taletrectinib Gains Chinese Approval for Advanced ROS1-Positive NSCLC
The decision is supported by results from the phase 2 TRUST-1 trial, which evaluated the safety and efficacy of taletrectinib in ROS1-positive NSCLC.
